Search

everythinglearnresearchcommunity

for

Search:↓

A user experimenting with an extreme hair loss treatment stack of Dutasteride, RU58841, 15 mg oral minoxidil, and microneedling, which sparked a debate among other users about the safety of this approach.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

The conversation discusses using a 4-in-1 spray containing minoxidil, tretinoin, caffeine, and melatonin for hair loss. Users consider the potential benefits of combining these ingredients, with some interest in a comprehensive approach to treatment.

The user has been using topical finasteride since October without improvement and is considering adding a caffeine product with dimethylglycine. Another user suggests caffeine is more promising and advises consulting a dermatologist about the lack of progress with finasteride.

Treatments for hair loss, including Minoxidil, finasteride, and RU58841. The post discusses the potential benefits of Pyrilutamide compared to RU58841 in terms of strength and longevity.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

A 33-year-old female with androgenic alopecia experienced alopecia areata patches after PRP treatment. She is seeking others' experiences with PRP worsening alopecia areata.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

A 21-year-old male shares progress pictures showing improvement in hair growth using daily topical minoxidil 5%, microneedling 1.25mm, and 500mg of saw palmetto. He reports new and healthy hair growth, indicating success in managing androgenic alopecia.

A new painless microneedle patch shows promise in reversing hair loss. The discussion focuses on potential new treatments beyond common options like Minoxidil, finasteride, and RU58841.

The conversation discusses the effectiveness of dermastamps versus dermarollers for hair loss treatment, with some users preferring dermastamps for precision and less hair damage. One user reports using a dermastamp with minoxidil, while others mention the convenience of dermapens and the cost-effectiveness of dermarollers.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

The user has been using oral Minoxidil, Finasteride, and Biotin for hair recovery and is considering adding topical Minoxidil and dermastamping to improve results. It is suggested to use micro-needling once a week with a 24-hour gap before applying topical Minoxidil.

The user experienced side effects from a hair loss treatment and is considering using pyrilutamide, alfatradiol, and possibly minoxidil. They are unsure about starting minoxidil immediately or waiting to see the effects of the other treatments.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Hair loss affects self-esteem and mental health, with treatments like finasteride and minoxidil commonly used. People feel misunderstood by those without hair loss and seek more empathy and better treatment options.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.